Premier (PINC) Q1 2025 earnings summary

Executive summary

• Fiscal Q1 2025 results slightly exceeded expectations for revenue and profitability, reaffirming full-year guidance.

• S2S Global direct sourcing business divested; Contigo Health divestiture ongoing, with results still included.

• Continued capital return to shareholders via dividends and share repurchases under $1B authorization.

• Strong member relationships and high contract renewal rates are driving deeper, data-driven collaborations.

• Strategic focus remains on technology-driven cost reduction and improved healthcare outcomes, less reliant on political/regulatory factors.

Financial highlights

• Total net revenue for Q1 was $248.1 million, down 8% year-over-year.

• GAAP net income was $72.9 million, up 75% year-over-year, benefiting from a $57 million non-operating gain from a derivative lawsuit settlement.

• Adjusted EBITDA was $62.4 million, down 33% year-over-year.

• Adjusted net income was $34.7 million, down 38%; adjusted EPS was $0.34, down 28%.

• Free cash flow was $16.2 million, up year-over-year, aided by lower capital expenditures and the lawsuit settlement.

• Cash and cash equivalents were $87 million as of September 30, 2024, with no outstanding balance on the $1 billion credit facility.

Outlook and guidance

• Fiscal 2025 guidance reaffirmed: total net revenue (ex-Contigo Health) $930M–$1.02B; adjusted EBITDA $235M–$255M; adjusted EPS $1.16–$1.28.

• Net administrative fees revenue projected at $495M–$525M; supply chain software/services $65M–$85M; capex $90M–$100M; effective tax rate 25%–27%.

• Free cash flow expected at 45%–55% of adjusted EBITDA; cash income tax rate under 5%.

• Sequential decline in GPO net administrative fees revenue expected in Q2 due to contract renewals.

• No update to adjusted EPS guidance until completion of the $200 million share repurchase program.